Methotrexate in rheumatoid arthritis. a five‐year prospective multicenter study

Arthritis & Rheumatism

Volumn 37, Issue 10, 1994, Pages 1492-1498

  Weinblatt, Michael E ^a   Kaplan, Herbert ^b   Germain, Bernard F ^c   Block, Sidney ^d   Solomon, Sheldon D ^e   Merriman, Richard C ^f   Wolfe, Frederick ^g   Wall, Bruce ^h   Anderson, Larry ⁱ   Gall, Eric ^j   Torretti, Dennis ^k   Weissman, Barbara ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Denver Arthritis Clinic PC   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d and Back Disease Associates ^*  (United States)

^e Baylor University Medical Center ^*  (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

^h MedVet Medical Center   (United States)

ⁱ Rheumatology Associates   (United States)

^j UNIVERSITY OF ARIZONA   (United States)

^k GEISINGER MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; METHOTREXATE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; METHOTREXATE; MIDDLE AGE; PREDNISONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME;

EID: 0027999764     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780371013     Document Type: Article

References (19)

1. Long‐term prospective study of the use of methotrexate in rheumatoid arthritis: update after a mean of 90 months.
2. Long‐term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84‐month update.
3. Low‐dose methotrexate compared with auranofln in adult rheumatoid arthritis: a thirty‐six‐week, double‐blind trial.
4. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire.
5. Preliminary criteria for clinical remission in rheumatoid arthritis.
6. Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placebo.
7. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36‐week randomized trial comparing methotrexate and auranofin.
8. Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study.
9. Pulse methotrexate therapy in rheumatoid arthritis: a controlled prospective roentgenographic study.
10. Prospective long term follow‐up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression.
11. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases.
12. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14‐year prospective evaluation of 1017 consecutive starts.
13. Long‐term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisone.
14. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long‐term treatment.
15. Determinants of serious liver disease among patients receiving low‐dose methotrexate for rheumatoid arthritis.
16. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate.
17. Pneumonitis complicating low‐dose methotrexate therapy in rheumatoid arthritis.
18. The relationship of pre‐existing lung diseaase to the occurrence of methotrexate pneumonitis in rheumatoid arthritis patients (abstract)
19. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors; four case reports and a review of the literature.